Format

Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2010 Mar 11;28(12):2465-71. doi: 10.1016/j.vaccine.2009.12.075. Epub 2010 Jan 9.

Staphylococcus aureus vaccine for orthopedic patients: an economic model and analysis.

Author information

1
Section of Decision Sciences and Clinical Systems Modeling, University of Pittsburgh, Pittsburgh, PA, USA. BYL1@pitt.edu <BYL1@pitt.edu>

Abstract

To evaluate the potential economic value of a Staphylococcus aureus vaccine for pre-operative orthopedic surgery patients, we developed an economic computer simulation model. At MRSA colonization rates as low as 1%, a $50 vaccine was cost-effective [<or=$50,000 per quality-adjusted life year (QALY) saved] at vaccine efficacy >or=30%, and a $100 vaccine at vaccine efficacy >or=70%. High MRSA prevalence (>or=25%) could justify a vaccine price as high as $1000. Our results suggest that a S. aureus vaccine for the pre-operative orthopedic population would be very cost-effective over a wide range of MRSA prevalence and vaccine efficacies and costs.

PMID:
20064479
PMCID:
PMC2833350
DOI:
10.1016/j.vaccine.2009.12.075
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center